Mark Conaway received his PhD in 1985 in Statistics from the University of Minnesota. Dr. Conaway has been a faculty member in the UVA School of Medicine since 1996 when he was one of the first faculty members hired in the newly formed Department of Health Evaluation Sciences.
During his time at the UVA School of Medicine, Dr. Conaway has established a number of collaborations in basic, clinical and translational research, primarily in the areas of Pediatrics, Neurology, Cardiovascular Medicine and Cancer. Dr. Conaway has done methodological work in developing reference centiles, in methods for handling missing data, and in the design of dose-finding studies in cancer. Dr. Conaway was elected a Fellow of the American Statistical Association in 2012.
Associate Chair for Faculty Development
Office of the Chair
Ph.D., Statistics, University of Minnesota, 1985
P.O. Box 800717
Old Med School, Room 3885
Design and analysis for clinical trials; Statistical methods for animal models; Longitudinal data.
Dr. Conaway’s areas of research interest include: missing data, design of phase I and phase II clinical trials, and developing reference norms.
PHS 7310 Clinical Trials Methodology (secondary instructor)
Cox D, Banton T, Moncrief M, Conaway M,Diamond A, and McCall A (2020) Minimizing Glucose Excursions (GEM) with Continuous Glucose Monitoring in Type 2 Diabetes: A Randomized Clinical Trial. Journal of the Endocrine Society, https://doi.org/10.1210/jendso/bvaa118
Lau C, Beller J, Boys A, Zhao Y, Phillips J, Cosner M, Conaway M, Petroni G, Charles E, Mehaffey H, Mannem H, Kron I, Krupnick A, and Linden J (2020) First In Human Lung Transplantation: Adenosine A2a Receptor Agonist (Regadenoson). The Journal of Heart and Lung Transplantation. Online ahead of print. https://doi.org/10.1016/j.healun.2020.02.003
Wages NA, Iasonos A, O’Quigley J and Conaway MR (2020) Coherence principles in interval-based dose finding Pharmaceutical Statistics. Volume19, Issue2, March/April 2020. Pages 137-144. DOI: 10.1002/pst.1974. PMID: 31692233 PMCID: PMC7065921.
Heymann P, Platts-Mills T, Woodfolk J, Borish L , Murphy D, Carper H, Conaway M, Steinke J, Muehling L, Teague G, .Kennedy J, Irani A-M, McGraw M , Early S, Wheatley L, Adams A, and Turner R (2020) Understanding the Asthmatic Response to an Experimental Rhinovirus Infection: Exploring the Effects of Blocking IgE. Journal of Allergy and Clinical Immunology. Online ahead of print. Feb 2020. https://doi.org/10.1016/j.jaci.2020.01.035
Conaway M. and Petroni G. (2019) The impact of early phase trial design in the drug development process. Clinical Cancer Research. 2019 Jan 15;25(2):819-827. PMID: 30327310 PMCID: PMC5712236
Brenton J, Woolbright E, Briscoe‐Abath C, Qureshi A, Conaway M and Goldman M (2019) Body mass index trajectories in pediatric multiple sclerosis. Developmental Medicine and Child Neurology. 61, Issue: 11. 1289-1308. Nov 2019
Horton BJ, Wages, NA and Conaway, MR (2019) Shift models for dose-finding in partially ordered groups. Clinical Trials, Volume: 16, Issue: 1, Pages: 32-40. Online ahead of print DOI: 10.1177/1740774518801599. PMID: 30309262 PMCID: PMC6684162
Wages N and Conaway M. (2018) Revisiting isotonic phase I design in the era of model-assisted dose-finding. Clinical Trials. Volume: 15 Issue: 5 Pages: 524-529 PMID:30101616. PMCID: PMC6133737
Conaway, M. (2017) Isotonic Designs for Phase I Trials in Partially Ordered Groups. Clinical Trials. Vol 14. 5: 491-498. PMID: 28776422
Conaway MR (2017) A design for phase I trials in completely or partially ordered groups. Statistics in Medicine. 2017. Volume 36, Issue 15, pp 2323-2332 PMID: PMC5571448